HK1127599A1 - 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial - Google Patents

2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial

Info

Publication number
HK1127599A1
HK1127599A1 HK09106680.3A HK09106680A HK1127599A1 HK 1127599 A1 HK1127599 A1 HK 1127599A1 HK 09106680 A HK09106680 A HK 09106680A HK 1127599 A1 HK1127599 A1 HK 1127599A1
Authority
HK
Hong Kong
Prior art keywords
inhibition
disease
beneficial
treatment
condition
Prior art date
Application number
HK09106680.3A
Other languages
English (en)
Inventor
Peter Hansen
Karolina Lawitz
Matti Lepistoe
Hans Loenn
Asim Ray
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38667997&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1127599(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1127599A1 publication Critical patent/HK1127599A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
HK09106680.3A 2006-05-08 2009-07-22 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial HK1127599A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79878606P 2006-05-08 2006-05-08
PCT/SE2007/000441 WO2007129962A1 (en) 2006-05-08 2007-05-07 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.

Publications (1)

Publication Number Publication Date
HK1127599A1 true HK1127599A1 (en) 2009-10-02

Family

ID=38667997

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09106680.3A HK1127599A1 (en) 2006-05-08 2009-07-22 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial

Country Status (21)

Country Link
US (1) US7998984B2 (de)
EP (1) EP2018375B1 (de)
JP (1) JP2009536196A (de)
KR (1) KR20090017573A (de)
CN (1) CN101490033A (de)
AR (1) AR060875A1 (de)
AT (1) ATE459615T1 (de)
AU (1) AU2007248950B2 (de)
BR (1) BRPI0711357A2 (de)
CA (1) CA2649813A1 (de)
CL (1) CL2007001282A1 (de)
DE (1) DE602007005120D1 (de)
ES (1) ES2339607T3 (de)
HK (1) HK1127599A1 (de)
IL (1) IL194948A0 (de)
MX (1) MX2008013836A (de)
NO (1) NO20084872L (de)
TW (1) TW200808763A (de)
UY (1) UY30328A1 (de)
WO (1) WO2007129962A1 (de)
ZA (1) ZA200809024B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
TW200808771A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
NZ575907A (en) * 2006-09-21 2011-03-31 Kyorin Seiyaku Kk 5-substituted benzoxazines
DE102007031397A1 (de) * 2007-07-05 2009-01-08 D2O Bioscience Group Ltd. Verwendung von Deuteriumoxid zur Behandlung von Virus-basierten Erkrankungen der Haut
EP2217591A4 (de) * 2007-11-06 2011-10-26 Astrazeneca Ab 2-pyrazinonderivate und ihre verwendung als inhibitoren neutrophiler elastase
EP2110132B1 (de) * 2008-04-20 2014-01-22 D2 Bioscience Group Ltd Verwendung von Deuteriumoxid als Elastase-Inhibitor
DE102009003942A1 (de) * 2009-01-07 2010-07-08 D2O Biosience Group Ltd., Hamilton Verwendung von Deuteriumoxid zur Behandlung Virus-basierter Erkrankungen des Auges
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
SG10201402346UA (en) * 2009-05-19 2014-10-30 Vivia Biotech Sl Methods for providing personalized medicine tests ex vivo for hematological neoplasms
KR20120099639A (ko) 2009-10-02 2012-09-11 아스트라제네카 아베 호중구 엘라스타제의 억제제로서 사용되는 2-피리돈 화합물
DE102010030187A1 (de) 2010-06-16 2011-12-22 Bayer Schering Pharma Aktiengesellschaft 4-Cyan-2-sulfonylphenyl)pyrazolyl-substituierte Pyridinone und Pyrazinone und ihre Verwendung
JP2013177318A (ja) * 2010-06-30 2013-09-09 Dainippon Sumitomo Pharma Co Ltd ジヒドロピリミジノン誘導体およびその医薬用途
JP5709999B2 (ja) 2011-08-01 2015-04-30 大日本住友製薬株式会社 ウラシル誘導体およびその医薬用途
US20140057920A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140057926A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US9102624B2 (en) 2012-08-23 2015-08-11 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US9409870B2 (en) 2014-12-15 2016-08-09 Chiesi Farmaceutici S.P.A. Compounds
UY36875A (es) 2015-09-02 2017-03-31 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
CN106674098B (zh) * 2016-12-23 2019-07-02 中国医科大学 N-(3-氰基-4-烷氧基苯基)吡啶甲酰胺类化合物及其用途
WO2019152977A2 (en) 2018-02-05 2019-08-08 Bio-Rad Laboratories, Inc. Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand
EP4031138A1 (de) 2019-09-17 2022-07-27 Mereo Biopharma 4 Limited Alvelestat zur verwendung bei der behandelung von transplantatabstossung, bronchiolitis-obliterans-syndrom und transplantat-gegen-wirtszelle
MX2022012942A (es) 2020-04-16 2023-01-11 Mereo Biopharma 4 Ltd Metodos que involucran el inhibidor de la elastasa de neutrofilo alvelestat para el tratamiento de enfermedades respiratorias mediadas por deficiencia de alfa-1 antitripsina.
IL312002A (en) 2021-10-20 2024-06-01 Mereo Biopharma 4 Ltd Neutrophil elastase inhibitors for use in the treatment of fibrosis

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1067079A (en) 1976-07-22 1979-11-27 Yamanouchi Pharmaceutical Co. Nitrogen-containing heterobicyclic compounds
DE2706977A1 (de) 1977-02-18 1978-08-24 Hoechst Ag Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung
EP0008864A1 (de) 1978-08-15 1980-03-19 FISONS plc Pyridopyrazin- und Chinoxalinderivate, Verfahren zu ihrer Herstellung, und sie enthaltende pharmazeutische Zusammensetzungen
JPH02152966A (ja) 1988-12-05 1990-06-12 Otsuka Pharmaceut Co Ltd ４−ヒドロキシカルボスチリル誘導体
US5521179A (en) 1991-04-18 1996-05-28 Zeneca Limited Heterocyclic amides
US5441960A (en) 1992-04-16 1995-08-15 Zeneca Limited 1-pyrimidinylacetamide human leukocyte elastate inhibitors
NZ335992A (en) 1996-12-05 2001-09-28 Amgen Inc Substituted pyrimidinone and pyridone compounds and methods of use
JPH1171351A (ja) 1997-08-29 1999-03-16 Ss Pharmaceut Co Ltd 置換キノロン誘導体及びこれを含有する医薬
US6949571B2 (en) 2000-06-12 2005-09-27 Eisai Co., Ltd. 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
TWI287004B (en) 2000-12-28 2007-09-21 Shionogi & Co A pyridone derivative having an affinity effect for cannabinoid 2 type receptor
JP4370164B2 (ja) 2001-08-14 2009-11-25 富山化学工業株式会社 新規なウイルス増殖阻害・殺ウイルス方法および新規なピラジンヌクレオチド・ピラジンヌクレオシド類似体
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
GB2383326A (en) 2001-12-20 2003-06-25 Bayer Ag Antiinflammatory dihydropyridines
MXPA03000145A (es) 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
ES2333214T3 (es) 2002-02-19 2010-02-18 SHIONOGI & CO., LTD. Antipruriticos.
CA2496815C (en) 2002-08-27 2011-04-26 Bayer Healthcare Ag Dihydropyridinone derivatives
GB2392910A (en) 2002-09-10 2004-03-17 Bayer Ag 2-Oxopyrimidine derivatives and their use as human leukocyte elastase inhibitors
TW200500341A (en) 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0302324D0 (sv) 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302323D0 (sv) 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
WO2005080372A1 (en) 2004-02-19 2005-09-01 Bayer Healthcare Ag Dihydropyridinone derivatives
EP1723121B1 (de) 2004-02-26 2012-07-25 Bayer Pharma Aktiengesellschaft 1,4-diaryldihydropyrimidin-2-one und deren verwendung als inhibitoren der humanen neutrophilelastase
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
KR200365249Y1 (ko) 2004-07-28 2004-10-21 추윤정 전동 퍼프
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
TW200700392A (en) 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
GB0512940D0 (en) 2005-06-24 2005-08-03 Argenta Discovery Ltd Compounds and their use
GB0605469D0 (en) 2006-03-17 2006-04-26 Argenta Discovery Ltd Multimers of heterocyclic compounds and their use
PT2024367E (pt) 2006-05-04 2010-12-03 Pulmagen Therapeutics Inflammation Ltd Tetra-hidropirrolopirimidinadionas e a sua utilização a título de inibidores da elastase de neutrófilos humana
TW200808771A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
US20110003858A1 (en) 2006-09-04 2011-01-06 Bergstroem Lena Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors
WO2008104752A1 (en) 2007-02-26 2008-09-04 Astrazeneca Ab Dihydropyridones as elastase inhibitors
WO2009058076A1 (en) 2007-11-02 2009-05-07 Astrazeneca Ab 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
EP2217591A4 (de) 2007-11-06 2011-10-26 Astrazeneca Ab 2-pyrazinonderivate und ihre verwendung als inhibitoren neutrophiler elastase
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628

Also Published As

Publication number Publication date
ZA200809024B (en) 2010-03-31
WO2007129962A1 (en) 2007-11-15
EP2018375A1 (de) 2009-01-28
ATE459615T1 (de) 2010-03-15
ES2339607T3 (es) 2010-05-21
US20090131486A1 (en) 2009-05-21
JP2009536196A (ja) 2009-10-08
CL2007001282A1 (es) 2008-01-18
TW200808763A (en) 2008-02-16
IL194948A0 (en) 2009-08-03
CA2649813A1 (en) 2007-11-15
AU2007248950A1 (en) 2007-11-15
AR060875A1 (es) 2008-07-16
DE602007005120D1 (de) 2010-04-15
US7998984B2 (en) 2011-08-16
NO20084872L (no) 2009-02-03
KR20090017573A (ko) 2009-02-18
UY30328A1 (es) 2008-01-02
BRPI0711357A2 (pt) 2011-09-27
EP2018375B1 (de) 2010-03-03
MX2008013836A (es) 2008-11-10
AU2007248950B2 (en) 2010-11-18
CN101490033A (zh) 2009-07-22

Similar Documents

Publication Publication Date Title
IL194948A0 (en) 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial
IL194949A0 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial
HUS1500034I1 (hu) Indolidon-származékok fibrózisos betegségek kezelésére vagy megelõzésére
IL193230A (en) Use of benzoxoborol derivatives in the preparation of drugs for the treatment of inflammatory diseases
ZA200707591B (en) Dihyrothienopyrimidines for the treatment of inflammatory diseases
ZA200808178B (en) Imidazolothiazole compounds for the treatment of disease
IL187739A0 (en) New 2-azetidinone derivatives for the treatment of hyperlipidaemic diseases
IL197934A (en) History of hydrobenzamide as hsp90 inhibitors and their use in the treatment of disease
IL196202A0 (en) Indazole derivatives for the treatment of hsp90-induced diseases
IL216967B (en) The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases
PT2049127E (pt) Derivados n-metanocarba para tratamento de doenças cardíacas
LT2100508T (lt) Augalų ligų kontrolės kompozicija ir būdas skirtas augalų ligų prevencijai ir kontrolei
PT2056805E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de reacção tecidular
EP1984017A4 (de) Verfahren zur therapie oder prophylaxe von durch erhöhte durchblutung verursachten gewebeschäden
IL201562A0 (en) Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases
EP2056858A4 (de) Behandlung von lungenerkrankungen
IL186022A0 (en) Dermatological compositions and salts for the treatment of dermatological diseases
PL2234631T3 (pl) Związki i metody stosowane w terapii choroby naczyniowej
EP1843781A4 (de) Zusammensetzung zur prävention, behandlung und diagnose von chronischen entzündlichen atemwegserkrankungen
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
GB0620695D0 (en) Composition and methods for the treatment of nurdegenerative disease
GB0623740D0 (en) Treatment of disease
ZA200708279B (en) Dermatological compositions and salts for the treatment of dermatological diseases
IL193319A0 (en) Alpha-1 antitrypsin for treating exacerbation episodes of pulmonary diseases
GB0425054D0 (en) Formamide derivatives for the treatment of diseases

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140507